<DOC>
	<DOCNO>NCT02009631</DOCNO>
	<brief_summary>This randomized Phase 1 study evaluate effect Veliparib cardiac repolarization patient solid tumor 's cancer recur longer respond current treatment .</brief_summary>
	<brief_title>A Study Evaluate Effects Veliparib Heart Rhythms Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<criteria>Confirmed solid malignancy metastatic unresectable standard curative measure therapy may provide clinical benefit exist longer effective . Subjects brain metastasis must clinically control neurologic symptom . Subject able swallow retain oral medication uncontrolled emesis . Subject adequate bone marrow , renal hepatic function per local laboratory reference range . Uncorrected serum potassium , serum magnesium , serum calcium free thyroxin ( FT4 ) thyroid stimulate hormone ( TSH ) outside normal reference range , grade 2 hyponatremia hypernatremia . Subject severe ECG morphologic abnormality make QTc evaluation difficult . Subject history cardiac conduction abnormality . Subject significant history cardiovascular disease . Subject receive anticancer therapy 21 day prior first dose study drug , recover good grade 2 high clinically significant adverse effect ( ) /toxicity ( ) previous therapy . Use drug know risk QT prolongation Torsades de Pointes within 7 day prior first study dose . Use tobacco nicotinecontaining product within 12 hour prior first study dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Solid Tumors</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Colon Cancer</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Gastric Cancer</keyword>
</DOC>